Bladder cancer is a common disease associated with high rates of morbidity and mortality.
Although immunotherapy approaches such as adoptive T-cell therapy and immune …

The clinical management of bladder cancer (BC) has become an increasing challenge due
to high incidence rate of BC, malignant behavior of cancer cells and drug resistance. The …

Bladder cancer (BCa) is one of the 10 most common cancers with high morbidity and
mortality worldwide. Long noncoding RNAs (lncRNAs), a large class of noncoding RNA …

Human bladder cancer (BCa) is one of the most commonly diagnosed malignancies
worldwide. It has high recurrence rates and low-grade malignancy, thus representing an …

Bladder cancer (BC) is a common and serious type of cancer that ranks among the top ten
most prevalent malignancies worldwide. Due to the high occurrence rate of BC, the …

Bladder cancer (BC) is the most common malignant tumor in the urinary system, and its early
diagnosis is conducive to improving clinical prognosis and prolonging overall survival time …

Long non-coding RNAs (lncRNAs) act as competing endogenous RNAs (ceRNAs) to
regulate mRNA expression through sponging microRNA in tumorigenesis and progression …

Background Long non-coding RNAs (lncRNAs) are essential regulators for various human
cancers. However, these lncRNAs need to be further classified for cancer. In the present …

Accumulating evidences indicate that long non-coding RNAs (lncRNAs) are indispensable
in cancer initiation and progression. Dysregulation of functional lncRNAs can promote the …

Bladder cancer (BC) is the ninth most common malignant disease and ranks fourteenth in
cancer mortality worldwide. Moreover, among cancers, the incidence and mortality of BC in …